Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors
02 December 2021 - 12:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the
"Company”), today announces the appointment of Mark Gilbert, M.D.,
to its Board of Directors. Dr. Gilbert served as Chief Medical
Officer of Juno Therapeutics prior to its acquisition by Celgene
Corporation and currently serves as Executive Vice President of
Research and Development at Acepodia. He succeeds outgoing Director
Hoonmo Lee, who has stepped down from Indaptus’ Board as part of
the transition, effective upon Dr. Gilbert’s appointment.
“We are delighted to have Dr. Gilbert join the
Indaptus Board of Directors. His successful record of shepherding
Juno’s novel CAR-T technology from bench to bedside brings valuable
experience to the Indaptus Board. The Company looks forward to
benefiting from his experience as we advance our new modality
immunotherapy pipeline into and through the clinic,” said Jeffrey
Meckler, Chief Executive Officer of Indaptus. “In addition, we
thank Mr. Lee for his service to our Board and wish him well in his
future endeavors.”
“I am excited to join the Indaptus Board of
Directors, as I believe their novel, multi-TLR agonist therapeutic
designed to safely prime and activate both the innate and adaptive
immune systems has the potential to change oncology treatment
paradigms and improve currently available immuno-oncology
therapeutics. I look forward to bringing my experience advancing
CAR-T therapies to bear with my fellow Directors and Senior
Management as we guide Indaptus into the clinic and beyond,” said
Dr. Gilbert.
Prior to joining Acepodia, Dr. Gilbert was Chief
Medical Officer of Juno Therapeutics where he led the clinical
development of some of the first CAR-T cell therapies. Before that,
he held leadership positions at Bayer Schering Pharmaceuticals,
Berlex Pharmaceuticals, Schering AG, and Immunex. Prior to his
pharmaceutical industry positions, Dr. Gilbert was a faculty member
at the Fred Hutchinson Cancer Research Center and the University of
Washington, where he trained in the laboratory of Dr. Phil
Greenberg, a scientific co-founder of Juno Therapeutics.
Dr. Gilbert received a B.S. in Biochemistry from
the University of Iowa and an M.D. from the University of Iowa
Medical School. He trained in internal medicine, infectious disease
and medical oncology at the University of California, San
Francisco, and the University of Washington, respectively.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company's approach is
based on the hypothesis that efficient activation of both innate
and adaptive immune cells and associated anti-tumor and anti-viral
immune responses will require a multi-targeted package of immune
system activating signals that can be administered safely
intravenously. Indaptus' patented technology is composed of single
strains of attenuated and killed, non-pathogenic, Gram-negative
bacteria, with reduced i.v. toxicity, but largely uncompromised
ability to prime or activate many of the cellular components of
innate and adaptive immunity. This approach has led to broad
anti-tumor and anti-viral activity, including safe, durable
anti-tumor response synergy with each of five different classes of
existing agents, including checkpoint therapy, targeted antibody
therapy and low-dose chemotherapy in preclinical models. Tumor
eradication by Indaptus technology has demonstrated activation of
both innate and adaptive immunological memory and, importantly,
does not require provision of or targeting a tumor antigen in
pre-clinical models. Indaptus has carried out successful GMP
manufacturing of its lead clinical oncology candidate, Decoy20, and
is currently completing other IND enabling studies.
Forward-Looking Statements
This press release contains forward-looking
statements with the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management's
expectations, beliefs and intentions regarding, among other things,
our product development efforts, business, financial condition,
results of operations, strategies, plans and prospects.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause our
actual results to differ materially from any future results
expressed or implied by the forward-looking statements. Many
factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: Indaptus' plans to develop and potentially commercialize
its technology, the timing and cost of Indaptus' planned
investigational new drug application and any clinical trials, the
completion and receiving favorable results in any clinical trials,
Indaptus' ability to obtain and maintain regulatory approval of any
product candidate, Indaptus' ability to protect and maintain its
intellectual property and licensing arrangements, Indaptus' ability
to develop, manufacture and commercialize its product candidates,
the risk of product liability claims, the availability of
reimbursement, the influence of extensive and costly government
regulation, and Indaptus' estimates regarding future revenue,
expenses capital requirements and the need for additional financing
following the merger. These risks, as well as other risks are
discussed in the proxy statement/prospectus that was included in
the registration statement on Form S-4 filed with the SEC in
connection with the merger. All forward-looking statements speak
only as of the date of this press release and are expressly
qualified in their entirety by the cautionary statements included
in this press release. We undertake no obligation to update or
revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Investor Contact:Will O'Connor Stern
Investor Relations +1
212-362-1200 will.oconnor@sternir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024